At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 388 enrolled
Drug / intervention
JNJ-64304500 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of JnJ-64304500 in Subjects With Moderately to Severely Active Crohn's Disease
In Brief
A Phase 2 clinical trial evaluating JNJ-64304500, Placebo, and 1 other intervention for Crohn Disease. Completed, enrolled 388 participants across 147 sites in 14 countries.
Detailed Summary
The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn Disease
CountriesBelgium, Bulgaria, Canada, France, Germany, Hungary, Japan, Poland, Romania, Russia, South Korea, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartAug 2016
Primary CompletionDec 2020
Study CompletionJan 2022
TodayJul 2026
First PostedAug 24, 2016
Enrollment StartAug 25, 2016
Primary CompletionDec 10, 2020
Study CompletionJan 24, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.9 years ago
Interventions
JNJ-64304500drug
Participants will receive JNJ-64304500 Subcutaneously.
Placebodrug
Participants will receive placebo Subcutaneously.
Ustekinumabdrug
Participants will receive ustekinumab as per the dosing regimen.